Engineering the Next Generation of Drug Discovery, Cell & Gene Therapy Applications Designed with CRISPR experts from the likes of CRISPR Therapeutics, Astrazeneca, AbbVie, Broad Institute, Casebia, Merck, Amgen and academic key opinion leaders, this year’s meeting encapsulates the critical scientific challenges and opportunities of CRISPR applications. Tackling delivery, safety, precision and efficiency best practice, further optimize your drug discovery, functional screening and translation of CRISPR-based cell and gene therapy into the clinic. With the first wave of CRISPR based therapeutic clinical trials firmly underway, the 5th Precision CRISPR Genome Editing Congress is perfectly timed to demonstrate the growing applications of CRISPR and unique approaches to gene therapy.
Conference + 2 Workshops: USD 4097.0
Conference + 1 Workshop: USD 3498.0
Conference Only: USD 2899.0
Workshop: USD 699.0
Speakers: TJ Cradick, CRISPR Therapeutics, Jesper Gromada, Exonics Therapeutics, Beeke Wienert, Gladstone Institutes, San Francisc, George M. Church, PhD., Harvard Medical School, Niren Murthy, UC Berkeley, PJ Brooks, NIH Common Fund Program on Somatic Cell Genome Editing, Neville Sanjana, New York Genome Center and Departments of Biology and Neuroscience, Namjin Chung, AbbVie, Leire Escudero-Ibarz, GSK, Ben Kleinstiver, Harvard Medical School, Jonathan Gootenberg, MIT, Omar Abudayyeh, MIT, David Alvarado, Merck, Guru Channabasavaiah, University of Nebraska Medical Center, Stuart Chambers, Amgen, Ultan McDermott, AstraZeneca, Honorary Faculty, Garrett Rettig, IDT, Eric Paul Bennett, University of Copenhagen, Abraham Scaria, Casebia Therapeutics, Megan van Overbeek, Caribou Biosciences, Inc., Dan Tierno, Bayer, Bio-Rad Representative, Horizon Representative, Cellecta Representative